(MENAFN- PR Newswire) Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial
NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference
being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
Continue Reading
ATS 2024 International Conference
May 17-22, 2024, San Diego, CA
Session : A104: Advances in the Diagnosis and Treatment of ILD
Abstract : Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis
Presentation : May 19, 3:00 p.m. - 4:15 p.m. PT
Location : San Diego Convention Center, Room 33A-C (Upper Level)
Presenter : Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust. Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
Trevi CANAL trial data being presented on May 19 at American Thoracic Society Conference
Post this
Registration details:
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and μ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit
and follow Trevi on X (formerly Twitter) and LinkedIn .
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
[email protected]
Media Contact
Rosalia Scampoli
914-815-1465
[email protected]
SOURCE Trevi Therapeutics, Inc.
MENAFN09042024003732001241ID1108075119
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.